Focal laser ablation for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new way to treat intermediate-risk prostate cancer using a targeted laser guided by micro-ultrasound and MRI. It aims to see if this less invasive approach is safe and effective for men who have not had prior prostate cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 40 and 80 years old.
- You have intermediate-risk prostate cancer (Gleason 7 with a primary grade of 3 or less).
- Your cancer is limited to one side of the prostate and the largest visible tumor is 15mm or smaller on MRI/micro-ultrasound.
- Your PSA level is below 15 ng/mL.
- You have not had any prior treatments for prostate cancer, including surgery, radiation, hormone therapy, or chemotherapy.
- You are able to complete questionnaires about your urinary, bowel, and sexual function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
This trial tests a newer, more precise type of radiation therapy for intermediate-risk prostate cancer using micro-ultrasound guidance to target the tumor. It aims to shorten treatment and reduce side effects while maintaining effectiveness.
This trial tests a laser procedure done through the skin between the scrotum and anus, guided by MRI and ultrasound, for men with certain prostate cancer types. It aims to heat and treat prostate cancer while checking safety and outcomes over follow-up visits.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This study tracks men with intermediate-risk prostate cancer who had a newer, targeted treatment that only treats the cancer area, not the whole prostate. It aims to see how well these treatments work in real life and may help guide future care.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.